Stanford, California 94305

  • Covid19

Purpose:

This study is to evaluate the feasibility and safety of treatment with related donor Human Leukocyte Antigen (HLA) matched or haploidentical allogeneic T regulatory cells in patients with COVID 19 induced ARDS. Study treatment will be administered in 1 to 2 doses, with the possibility of a second infusion given 14 days after the initial infusion.


Criteria:

Inclusion Criteria: - Age 18 years to 75 years - All patients at entry are required to be at high risk for the development of ARDS or receiving mechanical ventilatory support - Provision of signed written informed consent from the patient or patients legally authorized representative - Only patients who are committed to full life support (Do not resuscitate (DNR) allowed) - Initiation of study drug within 120 hours of the diagnosis of acute lung injury (ALI)/ARDS - COVID positive by PCR testing Exclusion Criteria: - Concurrent illness that shortens life expectancy to less than 6 months - Inability to obtain adequate study follow-up - Greater than 90 hours since first meeting ARDS criteria per the Berlin definition


NCT ID:

NCT04737161


Primary Contact:

Principal Investigator
Joe L Hsu, MD
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 12, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.